Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $65.86 Average Price Target from Brokerages

Posted by on Sep 25th, 2023

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) have earned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the last year is $65.86.

Several research firms have commented on AKRO. JPMorgan Chase & Co. boosted their price target on shares of Akero Therapeutics from $49.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 5th. Evercore ISI boosted their price target on shares of Akero Therapeutics from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 13th. Cantor Fitzgerald assumed coverage on shares of Akero Therapeutics in a research note on Tuesday, September 19th. They issued an “overweight” rating and a $69.00 price target for the company. HC Wainwright lifted their price objective on shares of Akero Therapeutics from $62.00 to $64.00 in a research report on Wednesday, June 7th. Finally, UBS Group assumed coverage on shares of Akero Therapeutics in a research report on Monday, August 28th. They set a “buy” rating and a $83.00 price objective for the company.

View Our Latest Report on Akero Therapeutics

Insider Activity at Akero Therapeutics

In related news, CEO Andrew Cheng sold 25,000 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $44.88, for a total value of $1,122,000.00. Following the completion of the sale, the chief executive officer now directly owns 447,680 shares of the company’s stock, valued at $20,091,878.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Catriona Yale sold 5,745 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $49.99, for a total value of $287,192.55. Following the completion of the sale, the insider now directly owns 46,627 shares of the company’s stock, valued at $2,330,883.73. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Cheng sold 25,000 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $44.88, for a total transaction of $1,122,000.00. Following the completion of the sale, the chief executive officer now directly owns 447,680 shares of the company’s stock, valued at $20,091,878.40. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 80,000 shares of company stock valued at $3,413,700 and sold 55,745 shares valued at $2,653,443. 9.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in AKRO. Swiss National Bank raised its holdings in shares of Akero Therapeutics by 7.8% in the first quarter. Swiss National Bank now owns 37,100 shares of the company’s stock valued at $526,000 after buying an additional 2,700 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Akero Therapeutics by 3.5% in the first quarter. Bank of New York Mellon Corp now owns 81,582 shares of the company’s stock valued at $1,157,000 after buying an additional 2,793 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Akero Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 15,580 shares of the company’s stock valued at $221,000 after buying an additional 5,750 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Akero Therapeutics by 33.9% in the first quarter. Dimensional Fund Advisors LP now owns 337,790 shares of the company’s stock valued at $4,794,000 after buying an additional 85,525 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Akero Therapeutics by 4.8% in the first quarter. Vanguard Group Inc. now owns 1,226,911 shares of the company’s stock valued at $17,410,000 after buying an additional 56,492 shares during the last quarter.

Akero Therapeutics Stock Down 5.2 %

Akero Therapeutics stock opened at $45.92 on Friday. Akero Therapeutics has a fifty-two week low of $25.21 and a fifty-two week high of $58.38. The company has a debt-to-equity ratio of 0.04, a quick ratio of 29.78 and a current ratio of 29.77. The firm has a 50 day moving average price of $46.85 and a 200 day moving average price of $45.38. The company has a market capitalization of $2.55 billion, a PE ratio of -17.94 and a beta of -0.94.

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) last posted its quarterly earnings results on Friday, August 11th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.01. Research analysts expect that Akero Therapeutics will post -2.7 earnings per share for the current year.

Akero Therapeutics Company Profile

(Get Free Report

Akero Therapeutics, Inc, a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.

Featured Articles

Analyst Recommendations for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.